Try our Advanced Search for more refined results

FTC Warns REMS Abuse Not Safe From Antitrust Law

By Melissa Lipman (June 19, 2014, 8:54 PM EDT) -- The Federal Trade Commission warned in an amicus filing in New Jersey federal court Tuesday that generic-drug makers should be allowed to sue brand-name companies under antitrust laws for allegedly gaming federal drug safety measures — known as risk evaluation and mitigation strategies programs — in Mylan Pharmaceuticals Inc.'s antitrust suit against Celgene Corp....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!